Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
about
Survival of cancer cells is maintained by EGFR independent of its kinase activityAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerInhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsReview of systemic therapies for locally advanced and metastatic rectal cancerTransforming growth factor-alpha prevents detachment-induced inhibition of c-Src kinase activity, Bcl-XL down-regulation, and apoptosis of intestinal epithelial cellsExpression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.Cell aggregation induces phosphorylation of PECAM-1 and Pyk2 and promotes tumor cell anchorage-independent growth.Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation.Jeremiah Metzger Lecture. Targeted cancer therapyComprehensive mapping of the human kinome to epidermal growth factor receptor signalingPotato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth.The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach.Colon cancer: a civilization disorder.Gestational diabetes mellitus alters apoptotic and inflammatory gene expression of trophobasts from human term placentaA longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal womenParathyroid hormone-related protein in preeclampsia: a linkage between maternal and fetal failures.Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis.Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor.Erlotinib: a new therapeutic approach for non-small cell lung cancer.Insulin, glucose, insulin resistance, and incident colorectal cancer in male smokers.Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trialMonoclonal antibody therapeutics and apoptosis.Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy.Locoregional therapy and systemic cetuximab to treat colorectal liver metastases.Novel targeted agents in the treatment of lung cancer.Targeting the epidermal growth factor receptorMonoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.Relationship between Preoperative ¹⁸F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer.Molecular biology of epidermal growth factor receptor inhibition for cancer therapy.Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinomaRecent developments in colorectal cancer treatment by monoclonal antibodies.
P2860
Q24309274-4A87A021-0773-4EBF-8566-2A047E4C3EBDQ24563539-7DF267D4-268A-49AD-A11A-6CD2442BB57BQ24810622-750B0C08-4590-455F-A5D6-4AF143EE6792Q27021105-E0863918-3FBC-45E9-9F1E-4B2BD2216293Q28580989-0F9EB2D3-9E84-4872-8C0F-6CFD450499D8Q33611056-C3D010FF-7C88-4709-A959-6CB2EE41C6F4Q33645244-A5E6127D-CDC2-470E-AF2A-6D6848EAAB94Q33950156-52903F88-3317-4536-82E7-77ACFC487BB3Q33958678-C513DF1F-7867-44F7-9697-E61E5CDAED0FQ33966943-DDFB146B-F76B-4BAE-832A-3426BB9A4752Q34066456-26D80729-66F0-4F32-9486-97C7F3120D98Q34103230-9ACF7CD4-A76D-4595-BC2E-6A1EA66DABADQ34104165-2DA5C8CA-083B-4AA3-A629-EC910A536A18Q34104980-F456E9AB-0B3B-4A08-A739-2446C8050D8FQ34198140-29BF221E-F827-4E7B-8EEF-6D5A69A86A15Q34199711-227BB59B-40C3-43BA-AE71-668BF3DDAF1BQ34236811-808A2936-515E-4CCD-BE56-255EBC0C9593Q34337529-2243576E-E807-4C5C-98EE-C380E74F5BC4Q34366865-700E460A-A687-4F3D-B8DC-F7216F9E7261Q34451934-F577F15D-F669-41B5-A052-406C2D395B91Q34482756-B023FAB2-4255-4229-9E3E-7470BCAA4D78Q34516496-9170F9B7-5B41-419E-80B4-7C1B0F5F005AQ34576155-533A1C2D-A762-4526-841B-45B1D3796E37Q34648886-5CA2647F-27BD-4740-880D-1AD29BD10369Q35001415-779D44DF-1D3B-4FCD-AE60-FE91833453B4Q35103237-7BAC865C-4F79-4DF7-91FC-7EF52C3825E5Q35185772-115EED8E-9E21-4F23-8E11-227BCDAFABA1Q35578858-D096FD1F-38FF-4D77-A428-AEE8E2BAA106Q35599794-D2A3CFF8-03E5-4BC1-94DF-5A3E9A752876Q35603396-43D415CE-8AE8-437A-AD18-8C2A0F411512Q35654360-AFEF644E-62DB-4EAB-B507-1925D5F17CB6Q35746556-784AC286-D5D8-4EEE-8521-6147EBC31CA9Q35790783-70500C50-085A-48CF-B327-27A78C5A4B0AQ35828552-9BEAEE07-4584-4739-BA95-6A33316ACE29Q35962555-FF577B2B-C68B-4EAD-B5A6-ADFAC51BE963Q36225230-838612B4-BF8D-4754-8298-1C10FAD823B9Q36418722-6E12CE53-CC88-4BFB-9B76-D5598E4829F8Q36481002-452347C0-4A40-4EFB-BC8D-8E42F817021FQ36611021-75751C73-63A0-41CF-8E29-C0453025B6EBQ36627254-31B914C8-B421-49C3-B25B-48681906E4FA
P2860
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Apoptosis induced by an anti-e ...... line and its delay by insulin
@ast
Apoptosis induced by an anti-e ...... line and its delay by insulin
@en
Apoptosis induced by an anti-e ...... line and its delay by insulin
@nl
type
label
Apoptosis induced by an anti-e ...... line and its delay by insulin
@ast
Apoptosis induced by an anti-e ...... line and its delay by insulin
@en
Apoptosis induced by an anti-e ...... line and its delay by insulin
@nl
prefLabel
Apoptosis induced by an anti-e ...... line and its delay by insulin
@ast
Apoptosis induced by an anti-e ...... line and its delay by insulin
@en
Apoptosis induced by an anti-e ...... line and its delay by insulin
@nl
P2093
P2860
P356
P1476
Apoptosis induced by an anti-e ...... line and its delay by insulin
@en
P2093
P2860
P304
P356
10.1172/JCI117871
P407
P577
1995-04-01T00:00:00Z